Payment overview · 2025
General Payments
$2,248.71
131 reported records · 25 companies
Healthcare provider profile · identity verified
Thomas W. Schneider, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JEFFERSON CITY, MO · NPI 1003875360
Verified facts
What the public records show
CMS Open Payments records show Thomas W. Schneider, M.D. received $2,248.71 in general payments during 2025 across 131 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 44 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Arexvy, Eliquis, Farxiga, Gemtesa, Linzess, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $405.27 | 18.0% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $235.38 | 10.5% | 17 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $182.40 | 8.1% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $178.27 | 7.9% | 15 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $166.48 | 7.4% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $160.24 | 7.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $154.71 | 6.9% | 10 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $150.06 | 6.7% | 9 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $83.52 | 3.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.69 | 3.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $71.08 | 3.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.72 | 2.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.74 | 1.8% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $40.14 | 1.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.08 | 1.6% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $31.67 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $26.87 | 1.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$26.36 | 1.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.18 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.69 | 0.9% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $17.63 | 0.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.80 | 0.7% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $14.69 | 0.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.54 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.50 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,248.71 | 131 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $316.54 | 19 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $237.03 | 11 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $193.64 | 8 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $182.40 | 10 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $157.64 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $128.33 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $109.40 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.34 | 6 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $83.52 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.69 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.76 | 5 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $71.32 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $71.08 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.72 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.72 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $61.66 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $61.66 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $60.63 | 5 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.58 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.77 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.74 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $40.14 | 2 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $36.26 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $31.67 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| KYPHON EXPRESS II KYPHOPAK TRAY Normalized: kyphon express ii kyphopak tray |
Device | Medtronic, Inc. | $26.36 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.63 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.63 | 2 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.80 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 34 | exact normalized | Medicare Part D |
| AREXVY arexvy |
2025 | Arexvy | 2024 | 52 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 410 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 157 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
80 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
52 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
261 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
157 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
410 | 74 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 809 | 380 |
| Amlodipine Besylate | Amlodipine Besylate | 737 | 202 |
| Furosemide | Furosemide | 667 | 162 |
| Pantoprazole Sodium | Pantoprazole Sodium | 500 | 146 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 496 | 162 |
| Gabapentin | Gabapentin | 494 | 108 |
| Omeprazole | Omeprazole | 493 | 139 |
| Losartan Potassium | Losartan Potassium | 476 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 453 | 126 |
| Eliquis | Apixaban | 410 | 74 |
| Potassium Chloride | Potassium Chloride | 410 | 98 |
| Azithromycin | Azithromycin | 408 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 408 | 107 |
| Lisinopril | Lisinopril | 393 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 380 | 91 |
| Montelukast Sodium | Montelukast Sodium | 372 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 342 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 327 | 81 |
| Lorazepam | Lorazepam | 286 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 276 | 70 |
| Alprazolam | Alprazolam | 269 | 40 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 267 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 262 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 261 | 50 |
| Meloxicam | Meloxicam | 255 | 65 |
| Metformin Hcl | Metformin Hcl | 252 | 76 |
| Simvastatin | Simvastatin | 241 | 67 |
| Cefuroxime | Cefuroxime Axetil | 223 | 146 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 54 |
| Levofloxacin | Levofloxacin | 219 | 119 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 215 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 56 |
| Glimepiride | Glimepiride | 208 | 67 |
| Citalopram Hbr | Citalopram Hydrobromide | 190 | 43 |
| Clonazepam | Clonazepam | 186 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 47 |
| Sertraline Hcl | Sertraline Hcl | 178 | 41 |
| Trazodone Hcl | Trazodone Hcl | 173 | 46 |
| Tramadol Hcl | Tramadol Hcl | 169 | 50 |
| Allopurinol | Allopurinol | 168 | 45 |
| Atenolol | Atenolol | 159 | 39 |
| Ozempic | Semaglutide | 157 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 31 |
| Warfarin Sodium | Warfarin Sodium | 133 | 20 |
| Carvedilol | Carvedilol | 130 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 122 | 22 |
| Finasteride | Finasteride | 121 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 109 | 21 |
| Mirtazapine | Mirtazapine | 104 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 96 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 22 |
| Synthroid | Levothyroxine Sodium | 91 | 22 |
| Buspirone Hcl | Buspirone Hcl | 82 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 80 | 25 |
| Doxepin Hcl | Doxepin Hcl | 77 | 16 |
| Diazepam | Diazepam | 73 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 49 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 71 | 50 |
| Alendronate Sodium | Alendronate Sodium | 69 | 16 |
| Pregabalin | Pregabalin | 66 | 17 |
| Donepezil Hcl | Donepezil Hcl | 65 | 11 |
| Cephalexin | Cephalexin | 63 | 46 |
| Metformin Hcl Er | Metformin Hcl | 63 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 63 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 63 | 13 |
| Benazepril Hcl | Benazepril Hcl | 59 | 12 |
| Celecoxib | Celecoxib | 59 | 16 |
| Lovastatin | Lovastatin | 59 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 58 | 14 |
| Propranolol Hcl | Propranolol Hcl | 58 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 17 |
| Ketoconazole | Ketoconazole | 55 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 52 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 52 | 52 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 14 |
| Fluconazole | Fluconazole | 52 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 11 |
| Ezetimibe | Ezetimibe | 50 | 14 |
| Nystatin | Nystatin | 50 | 26 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 47 | 15 |
| Spironolactone | Spironolactone | 47 | 12 |
| Sucralfate | Sucralfate | 46 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 12 |
| Lansoprazole | Lansoprazole | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 25 |
| Famotidine | Famotidine | 41 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 12 |
| Jardiance | Empagliflozin | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Colchicine | Colchicine | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 35 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 34 | 34 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 25 |
| Klor-Con M20 | Potassium Chloride | 33 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 17 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | 17 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 16 |
| Cefdinir | Cefdinir | 29 | 27 |
| Cholestyramine | Cholestyramine (With Sugar) | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 11 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Dulera | Mometasone/Formoterol | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Fentanyl | Fentanyl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Ursodiol | Ursodiol | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Dofetilide | Dofetilide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nucynta Er | Tapentadol Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,248.71 · 131 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, Arikayce, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, DUPIXENT, ELIQUIS, FARXIGA, FASENRA, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, Hillrom - Vest System Model 105 Home Care, INSPIRE, JASCAYD, JOURNAVX, KYPHON EXPRESS II KYPHOPAK TRAY, Kerendia, LEQVIO, LINZESS, MOUNJARO, NUCALA, NURTEC ODT, OFEV, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, Prolastin-C Liquid, REPATHA, Rybelsus, SHINGRIX, SMARTVEST, TEZSPIRE, Tyvaso, VYNDAQEL, Wegovy, XOLAIR, YUPELRI, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error